AnaptysBio names Christopher Murphy as CFO

AnaptysBio, Inc.

AnaptysBio, Inc.

ANAB

0.00
  • AnaptysBio appointed Christopher Murphy as chief financial officer.
  • Murphy previously served as CFO and CBO of Third Harmonic Bio; earlier roles included senior leadership at Horizon Therapeutics and life sciences investment banking at JMP Securities.
  • Owen Hughes joined board of directors; he is CEO of XOMA Royalty and previously led Sail Bio and Cullinan Oncology, with earlier corporate development roles at Intarcia Therapeutics and investment roles at Brookside Capital and Pyramis Global Advisors.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AnaptysBio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605110915PRIMZONEFULLFEED9717044) on May 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.